News >

MCL Expert Highlights Recent Advancements in Field

Angelica Welch
Published: Friday, Feb 16, 2018

Dr. Peter Martin

Peter Martin, MD
With the October 2017 FDA approval of the BTK inhibitor acalabrutinib (Calquence) for the treatment of patients with mantle cell lymphoma (MCL), the treatment armamentarium for this disease continues to expand.

Acalabrutinib joined ibrutinib (Imbruvica), which is another BTK inhibitor that has been approved for the treatment of patients with MCL since 2013. Long-term follow-up data out of the 2017 ASH Annual Meeting with single-agent ibrutinib demonstrated continued efficacy in patients with relapsed/refractory MCL.1 More than one-quarter of the patients in this pooled analysis remained progression free, and nearly half were alive at 3 years after treatment with ibrutinib. The median overall survival was 26.7 months and the complete response rate was 26.5%, with patients who were treated with ibrutinib following 1 line of prior therapy experiencing the best outcomes.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication